LXRXLEXICON PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $50M
- 730% YoY
- Operating margin
- -98.2%
- 97% YoY
- EBITDA
- −$48M
- 75% YoY
- Market cap
- $635M
- Employees
- 200,000
- $249 revenue each
- Net debt / EBITDA
- —
- −$35M net debt
- AI in 10-K
- 0.0
- mentions per 10K words
Takeover score 4 of 13
Fixable underperformance 1 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCYes25% of revenueOver 10% of revenue
- Payouts exceed cash flowNo-3% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo18% of assetsOver 40% of assets
- Shareholder dissentNo87% lowest supportAny vote under 80% support
Buyer economics 3 of 4
- Low revenue per employeeYes$249 · 7th pctBottom quartile of its SIC industry
- Quiet on AIYes0.0 per 10K words · 0th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$635M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$3M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1M | $6M | $50M | 730% |
| Operating income | −$87M | −$101M | −$172M | −$197M | −$49M | 75% |
| Net income | −$88M | −$102M | −$177M | −$200M | −$50M | 75% |
| Operating cash flow | −$87M | −$89M | −$162M | −$179M | −$68M | 62% |
| Capex | $1M | $1M | $470K | $1M | $0 | 100% |
| Stock-based comp | $11M | $12M | $14M | $13M | $13M | 7.3% |
| Buybacks | $3M | $864K | $824K | $2M | — |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| May 8, 2026 | Invus Global Management, LLC | SCHEDULE 13D/A | 9.6% | Passive |
| Feb 2, 2026 | Invus Global Management, LLC | SCHEDULE 13D/A | 10.0% | Passive |
| Dec 9, 2024 | Invus, L.P. | SC 13D/A | 50.3% | Passive |
| Jul 29, 2024 | Invus, L.P. | SC 13D/A | 50.3% | Passive |
| May 14, 2024 | Invus, L.P. | SC 13D/A | 50.3% | Passive |
| Mar 13, 2024 | Invus, L.P. | SC 13D/A | 50.5% | Passive |
| Jun 6, 2023 | Invus, L.P. | SC 13D/A | 50.4% | Passive |
| Aug 9, 2022 | Invus, L.P. | SC 13D/A | 20.6% | Passive |
| Aug 1, 2022 | Invus, L.P. | SC 13D/A | 50.7% | Passive |
| Jan 21, 2021 | Invus, L.P. | SC 13D/A | 27.5% | Passive |
Insider trading
- Open-market buys, 12 mo
- $3M · 8
- Open-market sells, 12 mo
- $0 · 0
- Net
- $3M
Pay vs performance
No pay-versus-performance disclosure yet.